All articles by Staff Writer
Staff Writer
Bruker Announces New D6 PHASERTM Benchtop X-Ray Diffraction (XRD) Platform for Materials Analysis and Advanced Research
Bruker Corporation (Nasdaq: BRKR), the global leader in X-ray diffraction, today announces the new D6 PHASERTM X-Ray Diffraction (XRD) system. The D6 PHASER is a new benchtop XRD platform designed with the analytical flexibility typically only available in larger, floor-standing systems. Unlike conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. With its wide range of capabilities, the D6 PHASER will enable more XRD applications for new markets and user communities.
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, participated in today’s U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee’s (VRBPAC) meeting, which resulted in a unanimous vote recommending updating the current COVID vaccine composition to a monovalent XBB-lineage.
Flen Health Receives 1.7 Million Grant from VLAIO for Groundbreaking Research on Recombinant Engineering of Wound-Healing Enzymes
Flen Health is proud to announce that it has been awarded a 1.7 million research and development grant by the Flanders Innovation & Entrepreneurship (VLAIO – for short) to leverage further its leading expertise in biological wound treatment research and development. The award represents the funding at approximately 60% of a 3.0 million project.
Thermo Fisher Scientific Introduces Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications.
Wound dressing FibDex® to be clinically tested for treatment of superficial dermal burns
UPM Biomedicals’ innovative wound dressing FibDex is undergoing a clinical investigation of performance and safety in patients with superficial dermal burns. The clinical investigation will be conducted by the Burn Centre of Uppsala University Hospital, Sweden, and is estimated to be completed in the beginning of the year 2025.
Randox acquires microfluidic tools and impedance flow cytometer developer Cellix Limited
Randox, a leading global diagnostics company and world leader in the development of diagnostic biochips, today announced the completion of its acquisition of Cellix Limited, a Dublin-based company that develops microfluidic tools and impedance flow cytometers for cell analysis.
Whether it’s AI, health apps, lab medicine or robotics, start-ups are shaking things up in the health sector and causing a stir at MEDICA
The agenda includes many highlights for and by the start-up scene
Danish National Genome Center Selects QIAGEN for Variant Interpretation in Oncology Genome Sequencing
QIAGEN today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) Interpret, is being deployed as a part of a national initiative in Denmark to offer sequencing-based solutions for cancer patients.
Certest will showcase its solutions in diagnostics and raw materials at AACC 2023
Certest, a company specialized in the development, manufacturing, and commercialization of solutions for the diagnosis of infectious diseases, is preparing to participate in the annual AACC exhibition, recognized as one of the largest global gatherings for the diagnostics sector. This year, the event will take place in Anaheim, California, on July 25th, 26th, and 27th.
Bruker Introduces Novel EVOQ™ DART-TQ+ for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments
At the 71st ASMS meeting, Bruker Corporation (Nasdaq: BRKR) highlights its commitment to develop novel technology and improved mass spec workflows for the applied markets requirements of robustness, ease-of-use, and highest confidence in food/beverage, forensic/toxicology, industrial and environmental analysis.